Li Sisi, Jing Jiajie, Chen Yueming, Chi Enjie, Wang Bingyan, Xie Ziwen, Yang Wenya, Shen Hongqiang, Pan Jianping
Department of Clinical Medicine, Hangzhou City University School of Medicine, 51 Huzhou Street, Hangzhou, 310015, People's Republic of China.
Institute of Translational Medicine, Hangzhou City University, 51 Huzhou Street, Hangzhou, 310015, People's Republic of China.
Cancer Immunol Immunother. 2025 Jul 24;74(9):275. doi: 10.1007/s00262-025-04106-z.
Chimeric antigen receptor (CAR) represents a novel targeted therapy that uses genetic engineering to modify effector cells for precise tumor cell targeting. Chimeric antigen receptor-T (CAR-T) cell immunotherapy, which employs T cells as effectors, has demonstrated significant efficacy in treating hematologic malignancies. However, its efficacy against solid tumors remains inadequate and is accompanied by toxic side effects, including cytokine release syndrome, neurotoxicity and on-target/off-tumor effects. In contrast to T cells, natural killer (NK) cells exhibit a broader source range and can non-specifically lyse tumor cells. Moreover, it can also reduce toxicity and side effects to some extent. This review comprehensively examines recent research progress on CAR-NK therapy for solid tumors, encompassing both in vivo and in vitro studies, with a focus on CAR-NK cell design and production methods. Drawing upon laboratory and clinical evidence, this review summarizes the current challenges and side effects associated with CAR-NK technology.
嵌合抗原受体（CAR）代表了一种新型的靶向治疗方法，它利用基因工程改造效应细胞，以精确靶向肿瘤细胞。以T细胞作为效应细胞的嵌合抗原受体T（CAR-T）细胞免疫疗法在治疗血液系统恶性肿瘤方面已显示出显著疗效。然而，其对实体瘤的疗效仍然不足，并且伴有毒性副作用，包括细胞因子释放综合征、神经毒性和靶向脱瘤效应。与T细胞不同，自然杀伤（NK）细胞来源范围更广，能够非特异性地裂解肿瘤细胞。此外，它还能在一定程度上降低毒性和副作用。本综述全面考察了CAR-NK疗法治疗实体瘤的最新研究进展，涵盖体内和体外研究，重点关注CAR-NK细胞的设计和生产方法。基于实验室和临床证据，本综述总结了与CAR-NK技术相关的当前挑战和副作用。
